Results 21 to 30 of about 14,860 (180)

Adverse Neuropsychiatric Events Associated with Varenicline: A Case Series

Psychiatry and Behavioral Sciences, 2021
Varenicline is an orally administered α4β2 nicotinic acetylcholine (Ach) receptor, partial agonist. This drug has been known to be more effective in the treatment of nicotine withdrawal than bupropion and nicotine replacement therapies ...
Burak Erman Menku, Taylan Altiparmak, Bahadir Genis, Behcet Cosar   +3 more
doaj   +1 more source

Implementation of a quality improvement project on smoking cessation reduces smoking in a high risk trauma patient population. [PDF]

, 2016
BackgroundCigarette smoking causes about one of every five deaths in the U.S. each year. In 2013 the prevalence of smoking in our institution's trauma population was 26.7 %, well above the national adult average of 18.1 % according to the CDC website. As
Carrens, Karen, Doben, Andrew, Gross, Ronald, Korntner, Samuel, Nahmias, Jeffry, Poola, Shiva   +5 more
core   +1 more source

Varenicline and Risk of Self-Harm: A Nested Case-Control Study. [PDF]

PLoS ONE, 2016
BACKGROUND:Smoking remains a serious public health concern. Pharmacotherapy for smoking cessation, including bupropion and varenicline, are proven means to increase quit rates.
Mina Tadrous, Diana Martins, Zhan Yao, Muhammad M Mamdani, David N Juurlink, Tara Gomes, Tony Antoniou   +6 more
doaj   +1 more source

Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial. [PDF]

PLoS ONE, 2016
UNLABELLED:Schizophrenic patients have a high rate of smoking and cognitive deficits which may be related to a decreased number or responsiveness of nicotinic receptors in their brains.
Robert C Smith, Revital Amiaz, Tian-Mei Si, Lawrence Maayan, Hua Jin, Sylvia Boules, Henry Sershen, Chunbo Li, Juanjuan Ren, Yanhong Liu, Mary Youseff, Abel Lajtha, Alessandro Guidotti, Mark Weiser, John M Davis   +14 more
doaj   +1 more source

Use of varenicline and nicotine replacement therapy in people with and without general practitioner-recorded dementia: retrospective cohort study of routine electronic medical records

BMJ Open, 2019
Objectives Our primary objective was to estimate smoking prevalence and prescribing rates of varenicline and nicotine replacement therapy (NRT) in people with and without general practitioner (GP)-recorded dementia.
Amy Taylor, Tim Jones, Taha Itani, Richard Martin, Gemma Taylor, Kyla Thomas, Neil Davies   +6 more
doaj   +1 more source

Varenicline Interactions at the 5-HT3 Receptor Ligand Binding Site are Revealed by 5-HTBP. [PDF]

, 2015
Cys-loop receptors are the site of action of many therapeutic drugs. One of these is the smoking cessation agent varenicline, which has its major therapeutic effects at nicotinic acetylcholine (nACh) receptors but also acts at 5-HT3 receptors.
Lillestol, Reidun K, Lummis, Sarah CR, Price, Kerry L, Ulens, Chris   +3 more
core   +3 more sources

Use of varenicline for smoking cessation treatment in UK primary care: an association rule mining analysis [PDF]

, 2014
BACKGROUND: Varenicline is probably the most effective smoking cessation pharmacotherapy, but is less widely used than nicotine replacement therapy. We therefore set out to identify the characteristics of numerically important groups of patients who ...
Action on Smoking and Health (ASH), AE Evins, British National Formulary (BNF), G Taylor, GD Garrison, IH Witten, John Britton, JS Taggar, K Cahill, KH Thomas, L Szatkowski, M Ragg, National Institute for Health and Care Excellence (NICE), National Institute for Health and Care Excellence (NICE), National Institute for Health and Care Excellence (NICE), R Peters, RM Anthenelli, Royal College of Physicians & Royal College of Psychiatrists, Sarah Lewis, TE Langley, The NHS Information Centre for Health and Social Care, U.S. Food and Drug Administration (FDA), UM Mohanasundaram, Y Huang, Yue Huang   +24 more
core   +3 more sources

Nicotine addiction : a review [PDF]

, 2013
Nicotine, the major psychoactive compound in tobacco, acts as a potent addictive drug in humans. The addictive nature of nicotine leads to more than 6 million deaths a year.
Di Giovanni, Giuseppe, Vella, Jacob
core   +1 more source

Varenicline is a smoking cessation drug that blocks alveolar expansion in mice intratracheally administrated porcine pancreatic elastase

Journal of Pharmacological Sciences, 2018
Smoking cessation is the most effective treatment in patients with emphysema and lung inflammation. The aim of the present study was to examine the effect of varenicline, a smoking cessation drug, on emphysema in porcine pancreatic elastase (PPE)-inhaled
Mitsuhisa Koga, Yuki Kanaoka, Tetsushi Tashiro, Nagisa Hashidume, Yasufumi Kataoka, Atsushi Yamauchi   +5 more
doaj   +1 more source

Efficacy and safety of pharmacotherapies for smoking cessation in anxiety disorders: Subgroup analysis of the randomized, active- and placebo-controlled EAGLES trial. [PDF]

, 2020
BackgroundSmoking rates are high in adults with anxiety disorders (ADs), yet little is known about the safety and efficacy of smoking-cessation pharmacotherapies in this group.MethodsPost hoc analyses in 712 smokers with AD (posttraumatic stress disorder
Anthenelli, Robert M, Ayers, Catherine R, Evins, A Eden, Heffner, Jaimee L, Lawrence, David, McRae, Thomas, Russ, Cristina   +6 more
core